Industry Newsdrug developmentendocrinologycorcept therapeutics
Corcept Therapeutics Receives Divergent Analyst Ratings
4.0
Corcept Therapeutics received mixed analyst coverage in November as H.C. Wainwright on Nov. 25 reiterated a Buy rating with a $145 target, projecting Korlym sales growth of 19–26% and supporting company guidance of $800–$850 million. Wolfe Research began coverage on Nov. 17 with a Peer Perform rating, citing patent litigation and antitrust risks while noting relacorilant’s PDUFA date of Dec. 30, 2025.
Key Points
- 1Reports: H.C. Wainwright reiterates Buy, $145 target, projects Korlym sales growth 19–26%.
- 2Explains: Volume rose 40% over two quarters, supporting company guidance of $800–$850 million.
- 3Advises: Wolfe Research warns legal risks; relacorilant PDUFA on Dec 30, 2025, affects valuation.
Scoring Rationale
Analyst-backed sales projections provide informative investor context, but company-specific, non-technical news limits broader market or technological relevance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
